Members of our COVID-19 healthcare and life sciences team bring substantial government credentials, including at the White House overseeing the HHS regulatory portfolio, leading incident response to a number of high-profile environmental, health, and safety crises in the national news, as well as successfully representing clients before agencies such as the U.S. Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS). Throughout the pandemic, we have brought our insider’s perspective to bear in counseling global tech clients and their U.S. health system and pharmaceutical partners in a range of multi-faceted, multinational business and philanthropic issues across borders, cultures, and fast-evolving legal terrain – from regulatory surveillance, intelligence, and advocacy, to novel import/export issues, to product counseling on biotech, biopharma, and digital health innovations and related approvals and strategic transactions, to environmental, health, and safety compliance program development and implementation. We are nimble, practical problem-solvers who can help your business adapt and respond—not only the coronavirus pandemic’s challenges, but its competitive opportunities as well.
COVID19, Healthcare, and the Life Sciences
Scroll to top